Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Redasemtide phase 2b study in acute ischemic stroke
2022-501890-38-00Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2023
- Modality
- Peptides
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of redasemtide in ischemic stroke (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Modified Rankin Scale score at Day 90. Started Jul 2023; status: completed.
02
Drugs
redasemtide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2022-501890-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501890-38-00.